Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity

Eileen F. Murphy, Paul D. Cotter, Aileen Hogan, Orla O'Sullivan, Andy Joyce, Fiona Fouhy, Siobhan F. Clarke, Tatiana M. Marques, Paul W. O'Toole, Catherine Stanton, Eamonn M M Quigley, Charlie Daly, Paul R. Ross, Robert M. O'Doherty, Fergus Shanahan

Research output: Contribution to journalArticlepeer-review

226 Scopus citations


Objective: The gut microbiota is an environmental regulator of fat storage and adiposity. Whether the microbiota represents a realistic therapeutic target for improving metabolic health is unclear. This study explored two antimicrobial strategies for their impact on metabolic abnormalities in murine diet-induced obesity: oral vancomycin and a bacteriocin-producing probiotic (Lactobacillus salivarius UCC118 Bac+). Design: Male (7-week-old) C57BL/J6 mice (9-10/group) were fed a low-fat (lean) or a high-fat diet for 20 weeks with/without vancomycin by gavage at 2 mg/day, or with L salivarius UCC118Bac+ or the bacteriocinnegative derivative L salivarius UCC118Bac- (each at a dose of 1×109 cfu/day by gavage). Compositional analysis of the microbiota was by 16S rDNA amplicon pyrosequencing. Results: Analysis of the gut microbiota showed that vancomycin treatment led to significant reductions in the proportions of Firmicutes and Bacteroidetes and a dramatic increase in Proteobacteria, with no change in Actinobacteria. Vancomycin-treated high-fat-fed mice gained less weight over the intervention period despite similar caloric intake, and had lower fasting blood glucose, plasma TNFα and triglyceride levels compared with diet-induced obese controls. The bacteriocin-producing probiotic had no significant impact on the proportions of Firmicutes but resulted in a relative increase in Bacteroidetes and Proteobacteria and a decrease in Actinobacteria compared with the non-bacteriocin-producing control. No improvement in metabolic profiles was observed in probiotic-fed diet-induced obese mice. Conclusion: Both vancomycin and the bacteriocin-producing probiotic altered the gut microbiota in dietinduced obese mice, but in distinct ways. Only vancomycin treatment resulted in an improvement in the metabolic abnormalities associated with obesity thereby establishing that while the gut microbiota is a realistic therapeutic target, the specificity of the antimicrobial agent employed is critical.

Original languageEnglish (US)
Pages (from-to)220-226
Number of pages7
Issue number2
StatePublished - Feb 2013

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity'. Together they form a unique fingerprint.

Cite this